Moderna, Inc. (NASDAQ:MRNA – Get Free Report) saw some unusual options trading on Thursday. Investors bought 72,594 put options on the company. This represents an increase of approximately 60% compared to the typical volume of 45,264 put options.
Moderna Trading Down 2.6 %
MRNA traded down $1.84 during trading on Thursday, reaching $68.02. 5,050,378 shares of the company’s stock were exchanged, compared to its average volume of 4,260,412. The company’s fifty day moving average price is $92.28 and its 200-day moving average price is $111.27. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The firm has a market capitalization of $26.07 billion, a PE ratio of -4.50 and a beta of 1.68.
Moderna (NASDAQ:MRNA – Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same quarter in the previous year, the business earned ($3.62) EPS. The business’s quarterly revenue was down 29.9% compared to the same quarter last year. As a group, equities analysts forecast that Moderna will post -9.52 EPS for the current year.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Moderna
Insider Activity
In other news, CFO James M. Mock sold 689 shares of the stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO James M. Mock sold 689 shares of the stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at $859,486.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,158 shares of company stock worth $11,167,312. Insiders own 15.70% of the company’s stock.
Hedge Funds Weigh In On Moderna
Several institutional investors and hedge funds have recently made changes to their positions in MRNA. Sanctuary Advisors LLC bought a new stake in Moderna in the 2nd quarter valued at $3,140,000. Teachers Retirement System of The State of Kentucky lifted its position in Moderna by 4.3% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 283,909 shares of the company’s stock valued at $33,714,000 after acquiring an additional 11,828 shares in the last quarter. Ariadne Wealth Management LP bought a new stake in Moderna in the 2nd quarter valued at $2,372,000. Granite Bay Wealth Management LLC bought a new stake in Moderna in the 2nd quarter valued at $524,000. Finally, Truist Financial Corp lifted its position in Moderna by 7.3% in the 2nd quarter. Truist Financial Corp now owns 18,657 shares of the company’s stock valued at $2,216,000 after acquiring an additional 1,275 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.
Moderna Company Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
- Five stocks we like better than Moderna
- The Significance of Brokerage Rankings in Stock Selection
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- How to Use the MarketBeat Excel Dividend Calculator
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Basic Materials Stocks Investing
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.